Last edition
News about "Fortress Biotech Unit Cyprium to Sell Rare Pediatr"
Fortress Biotech Unit Cyprium to Sell Rare Pediatric PRV for USD 205 Million
Fortress Biotech Inc and its majority-owned subsidiary Cyprium Therapeutics Inc announced that Cyprium has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 205 million, subject to closing.
Fortress Biotech Unit Cyprium To Sell Rare Pediatr | 25/02/2026 | By Darshana | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members